Compare TTEK & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEK | PCVX |
|---|---|---|
| Founded | 1966 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.0B |
| IPO Year | 1995 | 2020 |
| Metric | TTEK | PCVX |
|---|---|---|
| Price | $27.15 | $52.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $44.00 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 3.8M | 1.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $2,964,148,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.43 | N/A |
| P/E Ratio | $36.00 | ★ N/A |
| Revenue Growth | ★ 7.66 | N/A |
| 52 Week Low | $25.81 | $29.10 |
| 52 Week High | $43.14 | $65.00 |
| Indicator | TTEK | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 55.11 |
| Support Level | $26.98 | $44.85 |
| Resistance Level | $34.83 | $52.00 |
| Average True Range (ATR) | 0.97 | 2.11 |
| MACD | 0.08 | 0.80 |
| Stochastic Oscillator | 16.34 | 77.69 |
Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.